Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone732-329-8885
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$22.50 million
Profitability
Miscellaneous
Employees125
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Cytosorbents (NASDAQ:CTSO) Frequently Asked Questions
What is Cytosorbents' stock symbol?
Cytosorbents trades on the NASDAQ under the ticker symbol "CTSO."
How were Cytosorbents' earnings last quarter?
Cytosorbents Corp (NASDAQ:CTSO) announced its quarterly earnings results on Tuesday, August, 6th. The medical research company reported ($0.11) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.14) by $0.03. The medical research company earned $6.23 million during the quarter, compared to the consensus estimate of $6.53 million. Cytosorbents had a negative net margin of 72.43% and a negative return on equity of 105.97%. View Cytosorbents' Earnings History.
When is Cytosorbents' next earnings date?
What price target have analysts set for CTSO?
3 analysts have issued 12-month price targets for Cytosorbents' shares. Their forecasts range from $12.00 to $15.00. On average, they expect Cytosorbents' share price to reach $13.6667 in the next twelve months. This suggests a possible upside of 177.2% from the stock's current price. View Analyst Price Targets for Cytosorbents.
What is the consensus analysts' recommendation for Cytosorbents?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytosorbents in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cytosorbents.
What are Wall Street analysts saying about Cytosorbents stock?
Here are some recent quotes from research analysts about Cytosorbents stock:
- 1. Maxim Group analysts commented, "Cytosorbents reported 4Q18 with $5.5M in product sales, up 7% from $5.1M in 3Q18 and 30% from $4.2M y/y. For the year, revenue was $22.5M, a new record for the company and the first time revenue exceeded $20M. The company reported net income of ($5.4M) and $22.4M in cash." (3/8/2019)
- 2. HC Wainwright analysts commented, "We maintain our Buy rating of CytoSorbents and our 12-month price target of $15.00 per share. We derive our price target based on the average of two valuation methods: 1) price-sales multiple using 7x 2025 sales estimate discounted at 12%; and 2) price-earnings multiple using 25x 2025 earnings estimate discounted at 12%. (1) commercial; (2) partnership; (3) clinical; (4) financial; and (5) intellectual property." (3/8/2019)
Has Cytosorbents been receiving favorable news coverage?
Media headlines about CTSO stock have been trending positive this week, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cytosorbents earned a coverage optimism score of 2.5 on InfoTrie's scale. They also gave press coverage about the medical research company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the stock's share price in the next several days. View News Stories for Cytosorbents.
Who are some of Cytosorbents' key competitors?
Some companies that are related to Cytosorbents include Intersect ENT (XENT), Antares Pharma (ATRS), SI-Bone (SIBN), Orthopediatrics (KIDS), OraSure Technologies (OSUR), MiMedx Group (MDXG), GenMark Diagnostics (GNMK), Alphatec (ATEC), Utah Medical Products (UTMD), Westaim (WEDXF), Apyx Medical (APYX), Accuray (ARAY), Vapotherm (VAPO), Iradimed (IRMD) and Inovio Pharmaceuticals (INO).
What other stocks do shareholders of Cytosorbents own?
Who are Cytosorbents' key executives?
Cytosorbents' management team includes the folowing people:
- Dr. Phillip P. Chan, CEO, Pres & Director (Age 49)
- Ms. Kathleen P. Bloch MBA, CPA, CFO & Sec. (Age 64)
- Mr. Vincent J. Capponi MS, Chief Operating Officer (Age 61)
- Dr. Eric R. Mortensen, Chief Medical Officer (Age 59)
- Dr. Robert H. Bartlett, Co-Chairman of Cardiac Surgery Advisory Board & Consultant (Age 80)
Who are Cytosorbents' major shareholders?
Cytosorbents' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.22%), Vanguard Group Inc. (4.26%), Skylands Capital LLC (2.11%), Northern Trust Corp (1.10%), Sargent Investment Group LLC (1.03%) and Allianz Asset Management GmbH (1.02%). Company insiders that own Cytosorbents stock include Al Kraus, Kathleen P Bloch, Phillip P Chan and Vincent Capponi. View Institutional Ownership Trends for Cytosorbents.
Which major investors are selling Cytosorbents stock?
CTSO stock was sold by a variety of institutional investors in the last quarter, including Granite Investment Partners LLC, Wells Fargo & Company MN, AQR Capital Management LLC, Morgan Stanley and Allianz Asset Management GmbH. Company insiders that have sold Cytosorbents company stock in the last year include Al Kraus, Kathleen P Bloch, Phillip P Chan and Vincent Capponi. View Insider Buying and Selling for Cytosorbents.
Which major investors are buying Cytosorbents stock?
CTSO stock was bought by a variety of institutional investors in the last quarter, including Avenir Corp, Sargent Investment Group LLC, Skylands Capital LLC, Susquehanna International Group LLP, United Services Automobile Association, D. E. Shaw & Co. Inc., BlackRock Inc. and Charles Schwab Investment Management Inc.. View Insider Buying and Selling for Cytosorbents.
How do I buy shares of Cytosorbents?
Shares of CTSO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cytosorbents' stock price today?
One share of CTSO stock can currently be purchased for approximately $4.93.
How big of a company is Cytosorbents?
Cytosorbents has a market capitalization of $159.24 million and generates $22.50 million in revenue each year. The medical research company earns $-17,210,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Cytosorbents employs 125 workers across the globe.View Additional Information About Cytosorbents.
What is Cytosorbents' official website?
How can I contact Cytosorbents?
Cytosorbents' mailing address is 7 DEER PARK DRIVE SUITE K, MONMOUTH JUNCTION NJ, 08852. The medical research company can be reached via phone at 732-329-8885 or via email at [email protected]
MarketBeat Community Rating for Cytosorbents (NASDAQ CTSO)
MarketBeat's community ratings are surveys of what our community members think about Cytosorbents and other stocks. Vote "Outperform" if you believe CTSO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTSO will underperform the S&P 500 over the long term. You may vote once every thirty days.
